Trivalent antimonials induce degradation of the PML-RARα oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells

Blood

Volumn 92, Issue 11, 1998, Pages 4308-4316

  Müller, Stefan ^b   Miller Jr , Wilson H ^b   Dejean, Anne ^a  

^a INSTITUT PASTEUR   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY DERIVATIVE; ARSENIC TRIOXIDE; ONCOPROTEIN; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CELL NUCLEUS INCLUSION BODY; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION;

EID: 0032402135     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.11.4308.423k36_4308_4316     Document Type: Article

References (45)

1. de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A: The PML-RARα fusion mRNA generated by the t( 15; 17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675, 1991
2. Goddard AD, Borrow J, Freemont PS, Solomon E: Characterization of a zinc finger gene disrupted by the t(15; 17) in acute promyelocytic leukemia. Science 254:1371, 1991
3. Kakizuka A, Miller WH Jr. Umesono K, Warrell RP Jr, Frankel SR, Murty VVVS, Dmitrovsky E, Evans RM: Chromosomal translocation t(15; 17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 66:663, 1991
4. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, Grignan F, Pelicci PG: Structure and origin of the acute promyelocytic leukemia myl/RARα cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6:1285, 1991
5. Kastner P, Perez A, Lutz Y, Rochette-Egly C, Gaub M-P, Durand B, Lanotte M, Berger R, Chambon P: Structure, localization and transcriptional properties of two classes of retinoic acid receptor α fusion proteins in acute promyelocytic leukemia (APL): Structural similarities with a new family of oncoproteins. EMBO J 11:629, 1992
6. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, Pelicci PG: The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74:423, 1993
7. Rousselot P, Hardas B, Patel A, Guidez F, Gaken J, Castaigne S, Dejean A, de The H, Degos L, Farzaneh F, Chomienne C: The PML-RARα gene product of the t(15; 17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene 9:545, 1994
8. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM: A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:2551, 1997
9. He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, Cattoretti G, Pandolfi PP: Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci USA 94:5302, 1997
10. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ: Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulator sequences. Blood 89:376, 1997
11. David G, Terris B, Marchio A, Lavau C, Dejean A: The acute promyelocytic leukemia PML-RAR alpha protein induces hepatic preneoplastic and neoplastic lesions in transgenic mice. Oncogene 14:1549, 1997
12. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhao L, Gu LJ, Wang ZY: Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567, 1988
13. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704, 1990
14. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S, Degos L: All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: Structure-function relationship. Blood 76:1710, 1990
15. Warrell RP Jr, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385, 1991
16. Fenaux P, Chastang C, Castaigne S, Archimbaud E, Sanz M, Link H, Guerci A, Fegueux N, Zittoun R, Stoppa AM, Travade P, Lamy T, Maloisel F, Sadoun A, San Miguel J, Veil A, Rayon C, Conde E, Fey M, Bordessoule D, Ganser A, Bowen D, Dreyfus F, Huguet F, Tilly H, Guy H, Auzanneau G, Chomienne C, Degos L: Treatment of newly diagnosed acute promyelocytic leukemia (APL) with all-transretinoic acid (ATRA) followed by intensive chemotherapy (CT). Updated results of the European group. Blood 84:379a, 1994 (abstr, suppl 1)
17. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021, 1997
18. Dyck JA, Maul GG, Miller WH Jr, Chen JD, Kakizuka A, Evans RM: A novel macromolecular structure is a target of the promyelocyteretinoic acid receptor oncoprotein. Cell 76:333, 1994
19. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A, Dejean A: Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell 76:345, 1994
20. Koken MHM, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, Jong L de, Szostecki C, Calvo F, Chomienne C, Degos L, Puvion E, de The H: The t(15; 17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 13:1073, 1994
21. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, Pelicci PG, Miller WH: The PML/RARα oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 88:2826, 1996
22. Yoshida H, Kitamura K, Tanaku K, Omura S, Miyazaki T, Hachiya T, Ohno R, Naoe T: Accelerated degradation of PML-Retinoic acid receptor (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: Possible role of the proteosome pathway. Cancer Res 56:2945, 1996
23. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88:1052, 1996
24. 3 exerts dose-dependent dual effects on APL cells. Blood 89:3345, 1997
25. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354, 1997
26. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr: Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90:124, 1998
27. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de Thé H: Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:3978, 1997
28. Müller S, Matunis MJ, Dejean A: Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 17:61, 1998
29. Sternsdorf T, Jensen K, Will H: Evidence for covalent modifica- tion of the nuclear dot-associated proteins PML and Sp100 by PIC 1/ SUMO-1. J Cell Biol 139:1621, 1997
30. Kamitani T, Nguyen HP, Kito K, Fukuda-Kamitani T, Yeh ET: Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J Biol Chem 273:3117, 1998
31. Boddy MN, Howe K, Etkin LD, Solomon E, Freemont PS: PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13:971, 1996
32. Naredi P, Heath DD, Enns RE, Howell SB: Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells. J Clin Invest 95:1193, 1995
33. Bhattacharjee H, Li J, Ksenzenko MY, Rosen BP: Role of cysteinyl residues in metalloactivation of the oxyanion-translocating ArsAATPase. J Biol Chem 270:11245, 1995
34. Shi W, Dong J, Scott RA, Ksenzenko MY, Rosen BP: The role of arsenic-thiol interactions in metalloregulation of the ars operon. J Biol Chem 271:9291, 1996
35. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valenzi F, Berger R: NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77:1080, 1991
36. Rosenauer A, Raelson JV, Nervi C, Eydoux P, DeBlasio A, Miller WH: Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell-lines. Blood 88: 2671, 1996
37. Matunis MJ, Coutavas E, Blobel G: A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol 135:1457, 1996
38. Gaub M-P, Rochette-Egly C, Lutz Y, Ali S, Matthes H, Scheuer I, Chambon P: Immunodetection of multiple species of retinoic acid receptor alpha: evidence for phosphorylation. Exp Cell Res 201:335, 1992
39. Ali S, Lutz Y, Bellocq JP, Chenard-Neu MP, Rouyer N, Metzger D: Production and characterization of monoclonal antibodies recognising defined regions of the human oestrogen receptor. Hybridoma 12:391, 1993
40. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr : A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood 89:4282, 1997
41. Saitoh H, Pu RT, Dasso M: SUMO-1: Wrestling with a new ubiquitin-related modifier. Trends Biochem Sci 22:374, 1997
42. Johnson PR, Hochstrasser M: SUMO-1: Ubiquitin gains weight. Trends Cell Biol 7:408, 1997
43. Bueding E, Most H: Helminths: Metabolism, nutrition, and chemotherapy. Annu Rev Microbiol 7:295, 1953
44. Schulert AR, Rassoul AA, Mansour M, Girgis N, McConnell E, Farid Z: Biological disposition of antibilharzial antimony drugs. II. Antimony fate and uptake by Schistosomahaematobium eggs in man. Exp Parasitol 18:397, 1966
45. Dönges J: Therapie der Bilharziose. Dtsch Med Wochenschr 93:493, 1968